Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Irritability Should Be Considered When Diagnosing Bipolar Disorder In Children
A new study from Bradley Hospital and The Warren Alpert Medical School of Brown University, as well as two other institutions, adds to mounting evidence that clinicians consider irritability as a symptom when diagnosing pediatric bipolar disorder.

Campaign Welcome Parliamentary Report Exposing Serious Failings In Treatment For Alcohol Dependents Across England
UK Advocates (UKA), a new charitable campaign group dedicated to helping the still suffering alcoholic achieve lasting sobriety, has welcomed the All Party Parliamentary Group (APPG) on Alcohol Misuse report published which calls for urgent action to address serious shortcomings in the treatment of alcohol dependents in England.
News of the day
Alzheimer's Society Response To The Publication Of Revised NICE Guidance On Alzheimer's treatments
Thousands of people with Alzheimer"s will continue to be denied access to the only drug treatments for the disease following the publication of revised guidance by the NICE.
Medical Devices

Teva Announces Approval And Launch Of Tri-Lo Sprintec Tablets

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted approval for the Company"s Abbreviated New Drug Application (ANDA) to market a generic version of Ortho McNeil Janssen"s oral contraceptive, Ortho Tri-Cyclen® Lo. Shipment of this product, for which Teva"s trade name is Tri-Lo Sprintec, has commenced. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity. Annual sales of Ortho Tri-Cyclen® Lo were approximately $400 million in the United States for the twelve months that ended March 31, 2009 based on IMS sales data. Teva is currently involved in patent litigation concerning this product in the U.S. District Court for the District of New Jersey. A trial date has not been set. Teva Pharmaceutical Industries Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009